We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA said that it plans to gradually resume its on-site drugmaker inspections beginning in July with the intent to be back to normal operations by September.